Márton Mészáros
@marton_mes
starting sth new, aging, biobanks, target discovery. used to run ops and alzheimer's studies at http://novoic.com. studied as MD.
The strongest opinion I have is that the computational biology world has indexed far too heavily on gaining information from cells sitting in a dish. This is likely for historical reasons, in that LLMs work by just having a whole lot of text. But there's an important difference!
Solid take. Problem is most don't know where to start -> do fishing experiments. Value of a one patient's data/samples often wildly different than another patient's. Find most exciting patients first -> THEN get their samples-> no need to break the bank to find novel biology.
Biobankers are the next big thing in venture / company creation to usher in the promise of AI curing all diseases in the next ten years. We need tissue level data, cleanly tagged to phenotype and patient. Disease specific biobanks is something we're spending time on at Boom…
Why did BGE-105 fail in the STRIDES trial? Found some interesting threads to pull on from thousands of simulated data points. Built an AI copilot to help interpret what’s going on. Full article: open.substack.com/pub/brennanove…. tl;dr below:
I’ve recently been thinking about how and why to design an aging clinical trial with @marton_mes @NornGroup. Learned a lot about how we might incentivize trial economics (beyond “longevity drug = higher EV”) for more conservative stakeholders. Essay link and add’l thoughts below